ROS1 and non-small cell lung carcinoma: Crizotinib is already licensed in the treatment of non-small cell lung cancer and, if found to be effective in the treatment of ILC, may result in further trials investigating the inhibition of ROS1 as a novel therapeutic strategy for ILC (83).